Company Overview
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
Key Highlights
- Biotechnology · Healthcare
- Led by James McArthur
- 57 employees
- Based in Boston, MA
Price History
Loading…
Data from Twelve Data. Prices may be delayed.
Analyst Coverage
View All Coverage →No analyst coverage available.
Economic Calendar
View more →- Nov 12
Initial Jobless Claims
8:30 AM ET
Crypto Prices
View more →
Bitcoin (BTC)
73,785 −1.58%
Ethereum (ETH)
2,055 −3.30%
Solana (SOL)
83 −3.55%
Company Facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Boston, MA, US
- Incorporated
- May 6, 2022
- Website
- www.pepgen.com
Latest SEC Filings
View All Filings →- Current Report (Form 8-K)Nov 10, 2026